Comparison of Dosimetric Performance among Commercial Quality Assurance Systems for Verifying Pretreatment Plans of Stereotactic Body Radiotherapy Using Flattening-Filter-Free Beams.
10.3346/jkms.2016.31.11.1742
- Author:
Jin Beom CHUNG
1
;
Sang Won KANG
;
Keun Yong EOM
;
Changhoon SONG
;
Kyoung Sik CHOI
;
Tae Suk SUH
Author Information
1. Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea.
- Publication Type:Original Article
- Keywords:
Pretreatment Verification;
Delivery Quality Assurance;
Stereotactic Body Radiotherapy
- MeSH:
Humans;
Lung;
Prostate;
Radiosurgery*;
Spine
- From:Journal of Korean Medical Science
2016;31(11):1742-1748
- CountryRepublic of Korea
- Language:English
-
Abstract:
The purpose of this study was to compare the performance of different commercial quality assurance (QA) systems for the pretreatment verification plan of stereotactic body radiotherapy (SBRT) with volumetric arc therapy (VMAT) technique using a flattening-filter-free beam. The verification for 20 pretreatment cancer patients (seven lung, six spine, and seven prostate cancers) were tested using three QA systems (EBT3 film, I’mRT MatriXX array, and MapCHECK). All the SBRT-VMAT plans were optimized in the Eclipse (version 11.0.34) treatment planning system (TPS) using the Acuros XB dose calculation algorithm and were delivered to the Varian TrueBeam® accelerator equipped with a high-definition multileaf collimator. Gamma agreement evaluation was analyzed with the criteria of 2% dose difference and 2 mm distance to agreement (2%/2 mm) or 3%/3 mm. The highest passing rate (99.1% for 3%/3 mm) was observed on the MapCHECK system while the lowest passing rate was obtained on the film. The pretreatment verification results depend on the QA systems, treatment sites, and delivery beam energies. However, the delivery QA results for all QA systems based on the TPS calculation showed a good agreement of more than 90% for both the criteria. It is concluded that the three 2D QA systems have sufficient potential for pretreatment verification of the SBRT-VMAT plan.
